Browse Articles
Discover research articles across all indexed journals
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial
PURPOSE Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) face an unfavorable prognosis once first-line treatment fails; therefore, there is an unmet need for new treatment options. We evaluated the efficacy and safety of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) as an alternative therapy in patients with transplant-ineligible R/R DLBCL. METHODS The phase III POLARGO trial was a randomized, open-label, global study. Following a Pola-R-GemOx safety run-in (n = 15), patients with R/R DLBCL (not otherwise specified or transformed indolent lymphoma) ineligible for autologous stem cell transplant were randomly assigned 1:1 to receive Pola-R-GemOx or R-GemOx alone every 21 days for up to eight cycles. The primary end point was overall survival (OS). RESULTS In total, 255 patients were randomly assigned to receive Pola-R-GemOx (n = 129) or R-GemOx (n = 126). After a median follow-up of 24.6 months, patients receiving Pola-R-GemOx versus R-GemOx had a significantly lower risk of death (hazard ratio, 0.6 [95% CI, 0.43 to 0.83]; P = .0017) with a median OS of 19.5 months (95% CI, 13.3 to not estimable) versus 12.5 months (95% CI, 8.9 to 15.8). The most common grade 3/4 adverse events (AEs) were thrombocytopenia and neutropenia. Peripheral neuropathy was more common with Pola-R-GemOx (n = 73 [57%]) versus R-GemOx (n = 36 [29%]) and was primarily grade 1. Fatal AEs occurred in 15 (12%) and five (4%) patients in the Pola-R-GemOx and R-GemOx groups, respectively, and were largely driven by infections (including COVID-19). CONCLUSION Pola-R-GemOx significantly improved OS compared with R-GemOx, offering an additional treatment option in patients with transplant-ineligible R/R DLBCL.
Unveiling Auger recombination current component in rectification curves of silicon heterojunction solar cells
The rectification characteristics of semiconductor junctions are the basis for their application in diverse electronic and optoelectronic devices. Theoretically, the manifestation of Auger recombination under high positive bias voltage enables solar cells to achieve a high fill factor (FF); however, other recombination mechanisms and high series resistance make it difficult to be observed in the rectification curve. Here, the Auger recombination current component is identified in the rectification curves of silicon heterojunction solar cells featuring high FF and high open-circuit voltage (Voc). The current–voltage (I–V) characteristics of the device with high-conductivity nanocrystalline silicon oxide emitter demonstrate a distinct diode component exhibiting an ideality factor of n = 2/3, which is a definitive indicator of Auger recombination. The temperature-dependent I–V characteristics and Suns-Voc measurements reveal that suppression of series resistance and defect-mediated recombination is essential for unveiling the Auger recombination component.
Electroenzymatic CO <sub>2</sub> Fixation
ABSTRACT Replacing fossil resources with renewable alternatives for chemical production requires highly integrated, energy‐efficient, and selective CO 2 utilization processes. Electroenzymatic CO 2 fixation offers a promising pathway, combining high energy efficiency with unparalleled product selectivity, making it a viable approach for synthesizing complex molecules. This review outlines the fundamental principles of bioelectrocatalytic CO 2 conversion using reductases and carboxylases, providing an overview of the available enzymes, their product range, and key thermodynamic and kinetic considerations. By highlighting both the potential and limitations of electrochemical CO 2 fixation, this review aims to inform future progress in the discovery, engineering, and application of CO 2 ‐converting enzymes, with the ultimate goal of realizing the full potential of electroenzymatic CO 2 fixation for the sustainable synthesis of fine and specialty chemicals.
The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design
After five decades of CHOP-based therapy, the treatment landscape for patients with newly diagnosed large B-cell lymphoma (LBCL) is rapidly evolving. Novel agents, including antibody-drug conjugates, bispecific antibodies, targeted therapies, and chimeric antigen receptor (CAR) T-cell therapies, have demonstrated significant activity, raising the potential for improved outcomes from first-line treatment. However, this progress has introduced substantial complexity without a clear framework for clinical decision-making. Ongoing phase 3 trials employ heterogeneous designs, including differing control arms, eligibility criteria, and endpoints, yet share a common limitation: the inconsistent incorporation of biomarker-driven patient selection. As a result, cross-trial comparisons are challenging, and identifying the optimal regimen for an individual patient remains difficult. Although the POLARIX trial established polatuzumab-based therapy (R-CHP-pola) as superior to R-CHOP, many ongoing studies continue to use R-CHOP as the comparator, further complicating interpretation. Moreover, "R-CHOP + X" strategies evaluated in clinically defined populations without biologic stratification may yield modest benefits across heterogeneous groups, limiting their applicability to individual patients. These trends risk producing a fragmented landscape of effective yet non-comparable regimens without a principled framework for patient selection. We thus propose a harmonized, data-driven strategy to shape the next era of LBCL therapy: (1) pooled patient-level analyses; (2) standardized biomarker and minimal residual disease platforms; (3) AI-enabled predictive modeling integrating trial and real-world data; and (4) regulatory approaches promoting collaborative trial design and shared biomarker analyses. Ultimately, progress in LBCL will depend on aligning data, biology, and clinical decision-making to deliver precise, equitable, and effective care.
Precision Transfusion Medicine in the Omics Era
Transfusion medicine has practiced a form of precision medicine for decades through compatibility testing, infectious disease screening, component manufacturing, traceability, and hemovigilance. Yet blood is still often treated primarily as a commodity, collected, processed, stored, and transfused, rather than as a dynamic biologic product rich in molecular information. This Perspective argues that the field is uniquely positioned to extend its longstanding precision framework into a more molecular, longitudinal, and predictive era. Omics approaches, especially genomics and repeated metabolomic or proteomic profiling, can help define stable donor traits, track physiologic changes across the donation career, and connect donor biology to storage quality, post-transfusion performance, and recipient outcomes. Clinical metabolomics may eventually extend this framework to recipients, enabling deeper phenotyping across the full vein-to-vein continuum. This vision supports the emergence of the "blood unit+", a blood product enriched not only by compatibility and availability, but also by biologic context that may inform quality, resilience, and transfusion efficacy. At population scale, longitudinal donor testing could transform blood systems into distributed observatories of public health, or health weather stations, enabling molecular epidemiology, digital donor twins, and more meaningful reciprocity with donors. Integrated with artificial intelligence, these data could help strengthen donor recruitment and retention, by engaging a new generation of increasingly health-conscious donors, while supporting the resilience of blood systems facing demographic aging and shifting patterns of donor behavior, while linking donor biology, product behavior, and recipient response in ways no other field can presently match.
Associations between ambient air pollution and mortality during a 7-year ecological time-series study
Decentralized Clinical Trials in Hematology: the Promise and the Peril
Decentralized clinical trials (DCTs) are clinical studies where part or all trial-related activities occur remotely, reducing or eliminating the need for patients to physically visit a research site. By applying a more patient-centered design, DCTs have the potential to enhance patient access to clinical trials, improve enrollment and retention, and increase convenience, while simultaneously decreasing costs. This perspective explores the growing importance of DCTs, including the opportunity to facilitate engagement of patients with rare diseases and their broader implications for improving access to care. It also examines the challenges of implementing a DCT, comprising logistical complexities, reliance on technology, and regulatory considerations. Drawing upon our direct experience designing and executing a DCT for patients with Clonal Cytopenia of Undetermined Significance, we discuss our study design, share key pitfalls encountered and lessons learned regarding technology integration, site coordination, and patient engagement. Based on these experiences, we offer recommendations for optimizing DCT design, addressing challenges, and guiding future trials to fully realize the potential of decentralized models, ultimately fostering more equitable and patient-centric clinical research.
Effect of early skin-to-skin contact after vaginal birth on neonatal stress and day-5 bilirubin levels: a randomized trial
Generalized Analysis of Electrophilic Small Molecules
ABSTRACT Chemical construction almost universally employs highly customized product‐specific analytics. A transition toward generality will remove this critical bottleneck. Here we present how the fundamental chemical property of electrophilicity can be leveraged to generalize reaction analytics. By using a simple thiol probe we transform customized analytical schemes for electrophilic small molecules into a single generalized readout by tandem mass spectrometry. We apply this strategy to acrylamides commonly found in covalent inhibitors, and subsequently show how it can be extended to other classes of electrophilic small molecules. Application of this approach to high‐throughput chemical synthesis streamlines analysis, enabling rapid readouts of chemical analogs featuring acrylamides.
How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy that may result in major bleeding events and reduction of chemotherapy relative dose intensity. While there remain no widely available licensed therapies to manage CIT, major studies-including global pivotal phase 3 clinical trials of the thrombopoietin receptor agonists (TPO-RAs) romiplostim and avatrombopag in CIT- have been completed, along with additional supporting evidence from other clinical trials and observational studies. Like patients with chemotherapy-induced neutropenia, not all patients with CIT require treatment-but for those who do, it can have a major impact on a patient's oncologic care and outcomes. Proper management of CIT requires an understanding of the two clinical subtypes of CIT (persistent and nadir), the limited role of platelet transfusions and antifibrinolytics, and when and how to appropriately use TPO-RA support. In this article, 4 patient cases of CIT are used to illustrate common and challenging scenarios occurring in clinical practice. Built on a framework of published studies and supported by extensive clinical experience, appropriate treatment strategies for CIT are described in detail, with emphasis on proper patient selection, dosing, titration, and monitoring for the use of TPO-RAs in CIT.
Long-term trajectories of social adjustment and emotional/behavioral problems in pediatric post-acute COVID-19
Molecular Qubits for Anion Sensing by Tuning Electron Spin Relaxation via Axial Ligand Field
ABSTRACT Previously, we reported a new macrocyclic ligand, Mes N 6 , which enables the room‐temperature coherence of Cu( Mes N 6 )(OTf) 2 . In this study, we characterize a new series of complexes based on the square planar [M( Mes N 6 )] 2+ motif with different anions, X, (M = Co, Cu; X = SiF, OTf, and Cl) to tune the electron spin relaxation properties of Cu(II) and Co(II) through changes to the axial ligand. For Cu(II), a weakly‐coordinating SiF counterion minimizes orbital angular momentum (OAM) and prolongs longitudinal relaxation. An inverted trend is observed for Co(II) where a more donating Cl axial ligand decreases OAM and prolongs spin relaxation. The most pronounced effect occurs when the singly‐occupied molecular orbital (SOMO) is and its energy is most significantly impacted by anion binding. Using changes in coordination of Co(II) we detect chloride anions at 125 µM (0.25 equivalents) through relaxometry as measurable differences in longitudinal spin relaxation (T 1 ). Additionally, chloride coordination enables T m ‐based detection by Hahn echo of a Co(II)‐chloride species. Overall, we demonstrate predictable changes to electron spin relaxation through systematic variation of the axial ligand field, providing a strategy for molecular quantum sensing of anionic ligands.
Author Correction: Fractal nature of galaxy clustering in the updated CfA redshift catalog
Daily briefing: World Cup ‘hydration breaks’ miss the mark
Cross-domain microbial differences across freshwater and marine habitats in a tropical delta
Abstract Microbial communities are central to aquatic ecosystem functioning, yet integrated cross-domain comparisons of prokaryotic and microeukaryotic microbiomes remain underexplored in tropical regions, particularly in Bangladesh. Here, we investigated habitat-associated differences in microbial community structure across freshwater and marine ecosystems of the Bangladesh tropical delta using 16S and 18S rRNA gene amplicon sequencing and assessed inferred functional potential for prokaryotic communities. Six freshwater and ten seawater samples were analyzed, comprising eight newly generated datasets (six freshwater and two seawater) and eight previously published seawater datasets. Prokaryotic communities exhibited significantly higher alpha diversity in freshwater, whereas microeukaryotic diversity showed no significant habitat-associated differences after correction, despite a weak freshwater enrichment trend. Beta diversity revealed clear compositional separation between habitats for both domains, with prokaryotes exhibiting centroid shifts and microeukaryotes showing greater within-group dispersion. Taxonomic profiles showed seawater dominance by Gammaproteobacteria and Alphaproteobacteria, whereas freshwater communities were more evenly distributed across Bacteroidota, Actinomycetota, and Verrucomicrobiota. Microeukaryotic assemblages also displayed pronounced habitat-associated restructuring. Functional inference of prokaryotic communities indicated conservation of core pathways across habitats despite taxonomic turnover. Exploratory cross-domain correlation analysis identified mixed positive and negative associations, although none remained significant after multiple-testing correction. Collectively, these findings reveal consistent habitat-associated microbial differentiation across tropical freshwater and marine ecosystems and provide a comparative baseline for understanding cross-domain microbial biogeography in climate-sensitive aquatic environments.
Oxymatrine suppresses neuroinflammation via promoting microglial M2 polarization through FTO-dependent m6A demethylation of PGC-1α mRNA
Catalytic Functionalization of Unactivated π‐Bonds Enabled by Bidentate Directing Auxiliaries
ABSTRACT Catalytic functionalization of unactivated π‐bonds is a cornerstone of modern organic synthesis, offering efficient pathways to complex molecules. The emergence of the bidentate directing auxiliary strategy has fundamentally reshaped and significantly broadened the scope of transition‐metal‐catalyzed π‐bond functionalization. A key feature of this strategy is the formation of chelated intermediates where the bidentate directing auxiliary, tethered to the alkene or alkyne substrate, coordinates strongly to the transition metal catalyst. This chelation provides numerous advantages, including enhanced reaction kinetics, superior chemoselectivity, and improved catalyst efficiency, thereby enabling previously challenging reaction types on unactivated π‐bonds. This review highlights the recent significant progress in π‐bond functionalization enabled by bidentate directing auxiliaries, focusing on transformations catalyzed by palladium, nickel, copper, and other transition metals. We systematically discuss major reaction types, including hydrofunctionalization, difunctionalization, and C–H activation across various substrates, while emphasizing the underlying design principles that govern reactivity and selectivity in these systems.
Optimizing energy efficiency in wireless sensor networks through advanced cluster-based routing protocols
Abstract Wireless sensor networks (WSNs) have gained significant attention in recent research due to their potential in various applications. However, energy conservation remains a critical challenge, as the nodes within these networks operate on non-replaceable batteries. This paper introduces a cluster-based proactive routing protocol designed for three-tier energy-heterogeneous WSNs, aiming to enhance network lifetime and energy efficiency. The proposed protocol incorporates a modified threshold-based cluster head (CH) selection mechanism, which considers both the energy levels and distances of sensor nodes (SNs) relative to the base station (BS). This approach prioritizes nodes with higher energy and closer proximity to the BS, increasing their likelihood of being elected as CHs. Furthermore, this protocol minimizes the formation of unnecessary CHs, particularly for SNs with low remaining energy, thereby reducing energy waste. Moreover, the proposed protocol is modified to address the challenge of long transmission distances for low-power nodes by strategically deploying them in specific network zones, thus further optimizing energy efficiency. Simulation results demonstrate that the modified protocol outperforms existing protocols such as SEP, IMPLEACH, and EEECA-THWSN in terms of total network lifetime, stability period (first node death), half-node death, last node death, throughput, and normalized remaining energy. Numerically, the proposed protocol with normal zone improves network performance, achieving an increase of up to 27% in network lifetime and throughput compared to other protocols.
Enhanced CO <sub>2</sub> Activation Through Spin States Engineering Boosting Urea Electrosynthesis From Co‐Reduction of CO <sub>2</sub> and NO <sub>2</sub> <sup>−</sup>
ABSTRACT Electrocatalytic urea synthesis through co‐reduction of CO 2 and NO 3 − /NO 2 − has been considered as a sustainable alternative for urea production. However, the challenge for inert CO 2 activation results in inefficient C‐containing species coverage, leading to low urea yield and dominant NH 3 production. Herein, we design a Cu‐Mn dual‐site catalyst by co‐embedding CuO x clusters and single‐atomic Mn sites on C 3 N 4 ‐coated carbon nanotubes (CuO x /Mn 1 ‐C 3 N 4 @CNT) for urea electrosynthesis through co‐reduction of CO 2 and NO 2 − . Experimental and theoretical results show that the electron transfer from CuO x clusters to single‐atomic Mn sites induces Mn 3d electron delocalization and further spin configuration transformation from low spin states to high spin states. The electronic states regulation improves electron‐donation ability of Mn sites to substrates and enables the enhanced CO 2 activation and C‐containing intermediates adsorption behavior, facilitating coupling with N‐intermediates. Consequently, the CuO x /Mn 1 ‐C 3 N 4 @CNT catalyst achieves 60.2% urea Faradaic efficiency at −0.4 V (vs. RHE), 100% carbon selectivity over a record‐wide potential range of 300 mV, and exceptional 336 h cycling stability with 202.4 mg urea production. This work reveals a clear mechanism for performance enhancement through electronic interactions of dual sites and provides a dual‐substrate conversion catalyst design strategy.